DrugPatentWatch Database Updates: New Patent Additions
✉ Email this page to a colleague
DrugPatentWatch Database Updates: New Patent Additions
Applicant | Tradename | Generic Name | Dosage | NDA | Number | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Requested | Patent Expiration | Date Submitted | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nalpropion | CONTRAVE | bupropion hydrochloride; naltrexone hydrochloride | TABLET, EXTENDED RELEASE | 200063 | 001 | Sep 10, 2014 | RX | Yes | See Plans and Pricing | See Plans and Pricing | 2022-05-19 | U-1583 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY | |||
Gilead Sciences Inc | VEKLURY | remdesivir | POWDER | 214787 | 001 | Oct 22, 2020 | RX | Yes | See Plans and Pricing | See Plans and Pricing | 2020-11-12 | U-2984 | TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION | |||
Gilead Sciences Inc | VEKLURY | remdesivir | POWDER | 214787 | 002 | Oct 22, 2020 | RX | Yes | See Plans and Pricing | See Plans and Pricing | 2020-11-12 | U-2984 | TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION | |||
Gilead Sciences Inc | VEKLURY | remdesivir | POWDER | 214787 | 001 | Oct 22, 2020 | RX | Yes | See Plans and Pricing | See Plans and Pricing | 2020-11-12 | U-3249 | TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) | |||
Gilead Sciences Inc | VEKLURY | remdesivir | POWDER | 214787 | 002 | Oct 22, 2020 | RX | Yes | See Plans and Pricing | See Plans and Pricing | 2020-11-12 | U-3249 | TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) | |||
Gilead Sciences Inc | VEKLURY | remdesivir | POWDER | 214787 | 001 | Oct 22, 2020 | RX | Yes | See Plans and Pricing | See Plans and Pricing | 2020-11-12 | U-3367 | TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION | |||
Gilead Sciences Inc | VEKLURY | remdesivir | POWDER | 214787 | 002 | Oct 22, 2020 | RX | Yes | See Plans and Pricing | See Plans and Pricing | 2020-11-12 | U-3367 | TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Number | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Requested | >Patent Expiration | >Date Submitted | >Usecode | >Patented / Exclusive Use |